These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16821767)

  • 21. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel substituted benzoylguanidine derivatives as potent Na+/H+ exchanger inhibitors.
    Xu WT; Jin N; Xu J; Xu YG; Wang QJ; You QD
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3283-7. PubMed ID: 19433354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors.
    Gu YG; Weitzberg M; Clark RF; Xu X; Li Q; Zhang T; Hansen TM; Liu G; Xin Z; Wang X; Wang R; McNally T; Zinker BA; Frevert EU; Camp HS; Beutel BA; Sham HL
    J Med Chem; 2006 Jun; 49(13):3770-3. PubMed ID: 16789734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart.
    Wu L; Belardinelli L; Fraser H
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):372-9. PubMed ID: 18427280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.
    Kunz RK; Rumfelt S; Chen N; Zhang D; Tasker AS; Bürli R; Hungate R; Yu V; Nguyen Y; Whittington DA; Meagher KL; Plant M; Tudor Y; Schrag M; Xu Y; Ng GY; Hu E
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5115-7. PubMed ID: 18723346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
    Greco MN; Hawkins MJ; Powell ET; Almond HR; de Garavilla L; Hall J; Minor LK; Wang Y; Corcoran TW; Di Cera E; Cantwell AM; Savvides SN; Damiano BP; Maryanoff BE
    J Med Chem; 2007 Apr; 50(8):1727-30. PubMed ID: 17361995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.
    Elzein E; Ibrahim P; Koltun DO; Rehder K; Shenk KD; Marquart TA; Jiang B; Li X; Natero R; Li Y; Nguyen M; Kerwar S; Chu N; Soohoo D; Hao J; Maydanik VY; Lustig DA; Zeng D; Leung K; Zablocki JA
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6017-21. PubMed ID: 15546720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tramadol on myocardial ischemia-reperfusion injury.
    Bilir A; Erkasap N; Koken T; Gulec S; Kaygisiz Z; Tanriverdi B; Kurt I
    Scand Cardiovasc J; 2007 Aug; 41(4):242-7. PubMed ID: 17680512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
    Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
    J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment.
    Ikizler M; Erkasap N; Dernek S; Kural T; Kaygisiz Z
    Anadolu Kardiyol Derg; 2007 Dec; 7(4):404-10. PubMed ID: 18065337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A highly sensitive high-throughput luminescence assay for malonyl-CoA decarboxylase.
    Lo MC; Wang M; Kim KW; Busby J; Yamane H; Zondlo J; Yuan C; Young SW; Xiao SH
    Anal Biochem; 2008 May; 376(1):122-30. PubMed ID: 18294446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
    Plouvier B; Beatch GN; Jung GL; Zolotoy A; Sheng T; Clohs L; Barrett TD; Fedida D; Wang WQ; Zhu JJ; Liu Y; Abraham S; Lynn L; Dong Y; Wall RA; Walker MJ
    J Med Chem; 2007 Jun; 50(12):2818-41. PubMed ID: 17506538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932).
    Bagdanoff JT; Donoviel MS; Nouraldeen A; Carlsen M; Jessop TC; Tarver J; Aleem S; Dong L; Zhang H; Boteju L; Hazelwood J; Yan J; Bednarz M; Layek S; Owusu IB; Gopinathan S; Moran L; Lai Z; Kramer J; Kimball SD; Yalamanchili P; Heydorn WE; Frazier KS; Brooks B; Brown P; Wilson A; Sonnenburg WK; Main A; Carson KG; Oravecz T; Augeri DJ
    J Med Chem; 2010 Dec; 53(24):8650-62. PubMed ID: 21090716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives.
    Shirasaki Y; Nakamura M; Yamaguchi M; Miyashita H; Sakai O; Inoue J
    J Med Chem; 2006 Jun; 49(13):3926-32. PubMed ID: 16789748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors.
    Wallace DM; Haramura M; Cheng JF; Arrhenius T; Nadzan AM
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1127-30. PubMed ID: 17234415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.
    Chai W; Wu Y; Li G; Cao W; Yang Z; Liu Z
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E183-9. PubMed ID: 18003719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardioprotective effects of cyclosporine A in an in vivo model of myocardial ischemia and reperfusion.
    Xie JR; Yu LN
    Acta Anaesthesiol Scand; 2007 Aug; 51(7):909-13. PubMed ID: 17578461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.